Chief Scientific Officer
Heptares Therapeutics, BioPark, Broadwater Road, Welwyn Garden City, AL7 3AX, UK
Dr Marshall is a co-founder and Chief Scientific officer of Heptares Therapeutics Ltd a GPCR drug discovery company utilizing a novel structure based drug discovery approaches. She has a BSc in Biochemistry from Bath University and a PhD in Neuroscience from Cambridge. She has over 25 years’ experience in Drug Discovery with particular expertise on G protein coupled receptors obtained at GlaxoSmithKline and Millennium Pharmaceuticals. She is currently Chair of the CRUK Drug Discovery Committee and Vice-chair of the Wellcome Trust Seeding Drug Discovery Committee
Structure and fragment based drug discovery applied to G-protein coupled receptors
Structure based drug discovery has been challenging for G-protein-coupled receptors. Engineering receptors to increase thermostability enables the production of StaRs which can be purified and are amenable to structural approaches. Examples of using the technology to identify novel drug candidates for the A2A receptor and Orexin OX2 receptor will be given.